James D. Talton, Ph.D., is the President and CEO of Alchem Laboratories Corporation. Prior to joining Alchem, Dr. Talton served as the President and Chief Executive Officer of Nanotherapeutics, Inc. for seventeen years. He also is President of Nanopharmaceutics, Inc., President of Discovery Cure Institute, Inc., a Florida non-profit Corporation and serves on the Alumni Advisory Board for the University of Florida Department of Materials Science & Engineering.

Dr. Talton has developed multiple clinical-stage products as well as NanoFUSE® DBM, a sterile, FDA-cleared (K062459) easy-to-reconstitute bone graft. Leading multiple successful government programs, Dr. Talton has successfully won over $1 billion in contracts with government partners including NIH, DOD, and BARDA. Dr. Talton is an inventor on eleven U.S. patents and has authored several peer-reviewed publications and book chapters involved in drug delivery systems with a primary focus on drug analysis and controlled release formulations, pharmacokinetics and pulmonary drug delivery. Dr. Talton received his B.S. and M.S. in Materials Science & Engineering and his Ph.D. in Pharmaceutical Sciences from the University of Florida.